NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is...
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression;...
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to...
WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...
WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.